Global OPV cessation with at least one IPV routine immunization dose until 2024 is estimated to provide global incremental net benefits of approximately $16 billion compared to continued OPV use.
Does OPV cessation with IPV adoption improve health and economic outcomes compared to continued OPV use globally?
Global OPV cessation with IPV adoption is projected to provide approximately $16 billion in net economic benefits between 2013 and 2052 compared to continued OPV use.
Effect estimate: $16 billion
BACKGROUND: The Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) after interrupting all wild poliovirus (WPV) transmission, but many questions remain related to long-term poliovirus risk management policies. METHODS: We used an integrated dynamic poliovirus transmission and stochastic risk model to simulate possible futures and estimate the health and economic outcomes of maintaining the 2013 status quo of continued OPV use in most developing countries compared with OPV cessation policies with various assumptions about global inactivated poliovirus vaccine (IPV) adoption. RESULTS: Continued OPV use after global WPV eradication leads to continued high costs and/or high cases. Global OPV cessation comes with a high probability of at least one outbreak, which aggressive outbreak response can successfully control in most instances. A low but non-zero probability exists of uncontrolled outbreaks following a poliovirus reintroduction long after OPV cessation in a population in which IPV-alone cannot prevent poliovirus transmission. We estimate global incremental net benefits during 2013-2052 of approximately 16 billion (US2013) for OPV cessation with at least one IPV routine immunization dose in all countries until 2024 compared to continued OPV use, although significant uncertainty remains associated with the frequency of exportations between populations and the implementation of long term risk management policies. CONCLUSIONS: Global OPV cessation offers the possibility of large future health and economic benefits compared to continued OPV use. Long-term poliovirus risk management interventions matter (e. g. , IPV use duration, outbreak response, containment, continued surveillance, stockpile size and contents, vaccine production site requirements, potential antiviral drugs, and potential safer vaccines) and require careful consideration. Risk management activities can help to ensure a low risk of uncontrolled outbreaks and preserve or further increase the positive net benefits of OPV cessation. Important uncertainties will require more research, including characterizing immunodeficient long-term poliovirus excretor risks, containment risks, and the kinetics of outbreaks and response in an unprecedented world without widespread live poliovirus exposure.
Tebbens et al. (Thu,) conducted a other in Poliovirus (n=7,100,000,000). OPV cessation with at least one IPV routine immunization dose until 2024 vs. Continued OPV use (status quo) was evaluated on Global incremental net benefits (INB) ($16 billion). Global OPV cessation with at least one IPV routine immunization dose until 2024 is estimated to provide global incremental net benefits of approximately $16 billion compared to continued OPV use.